Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

por Isla, Dolores, Massuti, Bartomeu, Lázaro, Martín, de Alda, Lucía Ruiz, Gordo, Rocio, Ortega-Joaquín, Nuria, Oyagüez, Itziar
Publicado 2020